• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过共价片段探究蛋白激酶的半胱氨酸组

Probing the Protein Kinases' Cysteinome by Covalent Fragments.

作者信息

Wang Guiqun, Seidler Nico J, Röhm Sandra, Pan Yufeng, Liang Xiaojun Julia, Haarer Lisa, Berger Benedict-Tilman, Sivashanmugam Saran Aswathaman, Wydra Valentin R, Forster Michael, Laufer Stefan A, Chaikuad Apirat, Gehringer Matthias, Knapp Stefan

机构信息

Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 9, D-60438, Frankfurt am Main, Germany.

Structure Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 15, D-60438, Frankfurt am Main, Germany.

出版信息

Angew Chem Int Ed Engl. 2025 Feb 17;64(8):e202419736. doi: 10.1002/anie.202419736. Epub 2025 Jan 13.

DOI:10.1002/anie.202419736
PMID:39716901
Abstract

Protein kinases are important drug targets, yet specific inhibitors have been developed for only a fraction of the more than 500 human kinases. A major challenge in designing inhibitors for highly related kinases is selectivity. Unlike their non-covalent counterparts, covalent inhibitors offer the advantage of selectively targeting structurally similar kinases by modifying specific protein side chains, particularly non-conserved cysteines. Previously, covalent fragment screens yielded potent and selective inhibitors for individual kinases such as ERK1/2 but have not been applied to the broader kinome. Furthermore, many of the accessible cysteine positions have not been addressed so far. Here, we outline a generalizable approach to sample ATP-site cysteines with fragment-like covalent inhibitors. We present the development of a kinase-focused covalent fragment library and its systematic screening against a curated selection of 47 kinases, with 60 active site-proximal cysteines using LC/MS and differential scanning fluorimetry (DSF) assays, followed by hit validation through various complementary techniques. Our findings expand the repertoire of targetable cysteines within protein kinases, provide insight into unique binding modes identified from crystal structures and deliver isoform-specific hits with promising profiles as starting points for the development of highly potent and selective covalent inhibitors.

摘要

蛋白激酶是重要的药物靶点,但在500多种人类激酶中,仅针对一小部分开发出了特异性抑制剂。设计针对高度相关激酶的抑制剂时,一个主要挑战是选择性。与非共价抑制剂不同,共价抑制剂具有通过修饰特定蛋白质侧链(特别是非保守半胱氨酸)来选择性靶向结构相似激酶的优势。此前,共价片段筛选产生了针对个别激酶(如ERK1/2)的强效和选择性抑制剂,但尚未应用于更广泛的激酶组。此外,许多可及的半胱氨酸位置迄今尚未得到研究。在此,我们概述了一种用类片段共价抑制剂对ATP位点半胱氨酸进行取样的通用方法。我们展示了一个聚焦激酶的共价片段文库的开发过程,以及使用液相色谱/质谱(LC/MS)和差示扫描荧光法(DSF)分析,针对精心挑选的47种激酶、60个活性位点近端半胱氨酸进行的系统筛选,随后通过各种互补技术进行命中验证。我们的研究结果扩展了蛋白激酶中可靶向半胱氨酸的范围,深入了解了从晶体结构中确定的独特结合模式,并提供了具有前景的亚型特异性命中物,作为开发高效和选择性共价抑制剂的起点。

相似文献

1
Probing the Protein Kinases' Cysteinome by Covalent Fragments.通过共价片段探究蛋白激酶的半胱氨酸组
Angew Chem Int Ed Engl. 2025 Feb 17;64(8):e202419736. doi: 10.1002/anie.202419736. Epub 2025 Jan 13.
2
The Cysteinome of Protein Kinases as a Target in Drug Development.蛋白激酶半胱氨酸组作为药物开发的靶点。
Angew Chem Int Ed Engl. 2018 Apr 9;57(16):4372-4385. doi: 10.1002/anie.201707875. Epub 2018 Feb 2.
3
Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.利用化合物混杂性鉴定激酶组内可靶向半胱氨酸。
Cell Chem Biol. 2019 Jun 20;26(6):818-829.e9. doi: 10.1016/j.chembiol.2019.02.021. Epub 2019 Apr 11.
4
Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.确定人类激酶组中可用于共价抑制的半胱氨酸
J Med Chem. 2017 Apr 13;60(7):2879-2889. doi: 10.1021/acs.jmedchem.6b01815. Epub 2017 Apr 4.
5
Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches.基于计算方法的靶向半胱氨酸的共价结合位点鉴定
Mol Pharm. 2016 Sep 6;13(9):3106-18. doi: 10.1021/acs.molpharmaceut.6b00302. Epub 2016 Aug 10.
6
Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors.评估赖氨酸和半胱氨酸反应性以设计靶向共价激酶抑制剂。
J Am Chem Soc. 2019 Apr 24;141(16):6553-6560. doi: 10.1021/jacs.8b13248. Epub 2019 Apr 16.
7
Developing irreversible inhibitors of the protein kinase cysteinome.开发蛋白激酶半胱氨酸组的不可逆抑制剂。
Chem Biol. 2013 Feb 21;20(2):146-59. doi: 10.1016/j.chembiol.2012.12.006.
8
Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition.选择性靶向 PI3Kδ 激酶保守赖氨酸以实现共价激酶抑制的通用方法。
J Am Chem Soc. 2018 Jan 24;140(3):932-939. doi: 10.1021/jacs.7b08979. Epub 2018 Jan 9.
9
Targeting protein kinases with selective and semipromiscuous covalent inhibitors.使用选择性和半混杂共价抑制剂靶向蛋白激酶。
Methods Enzymol. 2014;548:93-116. doi: 10.1016/B978-0-12-397918-6.00004-5.
10
Fragment-based approaches to the discovery of kinase inhibitors.基于片段的激酶抑制剂发现方法。
Methods Enzymol. 2014;548:69-92. doi: 10.1016/B978-0-12-397918-6.00003-3.

引用本文的文献

1
Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies.通过表皮生长因子受体(EGFR)导向研究对靶向共价抑制剂进行分析和优化
J Med Chem. 2025 Aug 28;68(16):17917-17932. doi: 10.1021/acs.jmedchem.5c01661. Epub 2025 Aug 13.
2
A twist in the tale: shifting from covalent targeting of a tyrosine in JAK3 to a lysine in MK2.故事的转折:从共价靶向JAK3中的酪氨酸转变为靶向MK2中的赖氨酸。
RSC Med Chem. 2025 Aug 1. doi: 10.1039/d5md00440c.
3
Computational Design of Lysine Targeting Covalent Binders Using Rosetta.使用Rosetta进行赖氨酸靶向共价结合物的计算设计
J Chem Inf Model. 2025 May 29. doi: 10.1021/acs.jcim.5c00212.
4
Screening of Covalent Kinase Inhibitors Yields Hits for Cysteine Protease USP7 / HAUSP.共价激酶抑制剂的筛选产生了针对半胱氨酸蛋白酶USP7 / HAUSP的活性化合物。
Drug Des Devel Ther. 2025 Mar 25;19:2253-2284. doi: 10.2147/DDDT.S513591. eCollection 2025.